Overview

Useful For
Serologic detection of recent or past parvovirus B19 infection

Highlights
This assay may be used to determine the serostatus of patients at risk for infection with parvovirus B19.

Results may be used, alongside clinical evaluation and other laboratory findings, to determine if the patient has recent or past infection with parvovirus B19.

Profile Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Reporting Name</th>
<th>Available Separately</th>
<th>Always Performed</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARVG</td>
<td>Parvovirus B19 Ab, IgG, S</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>PARVM</td>
<td>Parvovirus B19 Ab, IgM, S</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>PARVN</td>
<td>Parvovirus B19 Ab</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Method Name
Enzyme Immunoassay (EIA)

NY State Available
Yes

Specimen

Specimen Type
Serum

Advisory Information
This test is intended for patients with at least 7 days of symptoms or asymptomatic individuals with recent exposure to parvovirus B19.

For patients with acute, symptomatic presentation, order either PARVP / Parvovirus B19, Molecular Detection, PCR, Plasma or PARVO / Parvovirus B19, Molecular Detection, PCR, Varies.

Specimen Required

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL

Forms
If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.

Specimen Minimum Volume
0.5 mL

Reject Due To

<table>
<thead>
<tr>
<th>Condition</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross hemolysis</td>
<td>Reject</td>
</tr>
<tr>
<td>Gross lipemia</td>
<td>Reject</td>
</tr>
<tr>
<td>Gross icterus</td>
<td>Reject</td>
</tr>
<tr>
<td>Other</td>
<td>Heat-inactivated specimen</td>
</tr>
</tbody>
</table>

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td>Refrigerated (preferred)</td>
<td>14 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frozen</td>
<td>14 days</td>
<td></td>
</tr>
</tbody>
</table>

Clinical and Interpretive

Clinical Information

Parvovirus B19 is the causative agent of fifth disease (ie, erythema infectiosum, slapped cheek syndrome), which usually produces a mild illness characterized by an intensive erythematous maculopapular facial rash. Most outbreaks of parvovirus infection are acquired by direct contact with respiratory secretions and primarily occur in the spring. Close contact between individuals is responsible for infection in schools, day care centers, and hospitals. The virus has also been associated with fetal damage (hydrops fetalis), aplastic crisis, and arthralgia. Infection during pregnancy presents the risk of transmission to the fetus that may cause intrauterine death. The rate of fetal death following maternal infection ranges between 1% and 9%.

Parvovirus B19 preferentially replicates in erythroid progenitor cells.(1) Infection with parvovirus B19 occurs early in life, and the virus is transmitted by respiratory secretion and occasionally by blood products. The prevalence of parvovirus B19 IgG antibodies increases with age. The age-specific prevalence of antibodies to parvovirus is 2% to 9% of children under 5 years, 15% to 35% in children 5 to 18 years of age, and 30% to 60% in adults (19 years or older).

Most acute infections with parvovirus B19 are diagnosed in the laboratory by serologically detecting IgG and IgM class antibodies to the virus using an enzyme-linked immunosorbent assay testing.

Reference Values

IgG: Negative

IgM: Negative

Interpretation
**Test Definition: PARVS**

Parvovirus B19 Ab, IgG and IgM, S

<table>
<thead>
<tr>
<th>Parvovirus B19 IgM</th>
<th>Parvovirus B19 IgG</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>Negative</td>
<td>No antibody to Parvovirus B19 detected. Acute infection cannot be ruled out as antibody levels may be below the limit of detection. If clinically indicated, a second serum should be submitted in 14 to 21 days.</td>
</tr>
<tr>
<td>Negative</td>
<td>Positive</td>
<td>Results suggest past infection.</td>
</tr>
<tr>
<td>Equivocal</td>
<td>Positive or negative</td>
<td>Recommend follow-up testing in 10 to 14 days if clinically indicated.</td>
</tr>
<tr>
<td>Positive</td>
<td>Positive, negative or equivocal</td>
<td>Results suggest recent infection and should be interpreted in the context of clinical presentation.</td>
</tr>
</tbody>
</table>

The presence of IgM class antibodies suggests recent infection. The presence of IgG antibodies only is indicative of past exposure.

Both IgG and IgM may be present at or soon after onset of illness and reach peak titers within 30 days. Because IgG antibody may persist for years, diagnosis of acute infection is made by the detection of IgM antibodies.

**Cautions**

Specimens drawn prior to seroconversion may yield negative IgM or IgG antibody results, while specimens drawn after IgM antibody levels have begun to decline may yield negative IgM antibody results. Follow-up testing of convalescent samples may be beneficial to establish infection status.

The continued presence or absence of antibodies cannot be used to determine the success or failure of therapy.

Test results of specimens from immunocompromised patients may be difficult to interpret.

Testing should not be performed as a screening procedure for the general population. Testing should only be done when clinical evidence suggests the diagnosis of parvovirus B19-associated disease.

The performance of this test has not been established on neonates and immunocompromised patients.

Specimens containing antinuclear antibodies may produce equivocal or positive test results in the IgM assay.

Epstein-Barr virus-positive specimens may produce positive or equivocal test results in the IgM assay.

Assay performance characteristics have not been established for matrices other than serum.

**Clinical Reference**


Performance

Method Description
Antibody to parvovirus B19 is detected by a sandwich EIA for the detection of IgG or IgM class antibodies in serum or plasma (Biotrin, Dublin, Ireland). Specific parvovirus B19 antibodies in specimens bind to antigen-coated microtiter wells. Following a wash step, peroxidase-labeled rabbit-antihuman IgG is added that binds to parvovirus antibody. The antigen-antibody complex is detected by the addition of substrate, which turns blue in the presence of the enzyme peroxidase.(Anderson LJ, Tsou R, Parker RA, et al: Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol 1986;24[4]:522-526. Package insert: Parvovirus B19 IgG and IgM Enzyme Immunoassay, DiaSorin, Biotrin, Dublin, Ireland. 10/2012)

PDF Report
No

Day(s) and Time(s) Test Performed
Monday through Friday; 11 a.m.

Analytic Time
Same day/1 day

Maximum Laboratory Time
3 days

Specimen Retention Time
14 days

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test has been modified from the manufacturer’s instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
86747 x 2

LOINC® Information
### Test Definition: PARVS
Parvovirus B19 Ab, IgG and IgM, S

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARVS</td>
<td>Parvovirus B19 Ab, IgG and IgM, S</td>
<td>34950-6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARVG</td>
<td>Parvovirus B19 Ab, IgG, S</td>
<td>29660-8</td>
</tr>
<tr>
<td>PARVM</td>
<td>Parvovirus B19 Ab, IgM, S</td>
<td>40658-7</td>
</tr>
<tr>
<td>PARVN</td>
<td>Parvovirus B19 Ab Interpretation</td>
<td>58737-8</td>
</tr>
</tbody>
</table>